Rapt Therapeutics Inc (RAPT)

Jan 9, 2025, 8:00 AM EST - 6 weeks ago

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:00 AM EST - 6 weeks ago

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

Dec 23, 2024, 7:10 AM EST - 2 months ago

RAPT Therapeutics Announces $150 Million Private Placement

Nov 11, 2024, 10:34 AM EST - 3 months ago

Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury

Jul 24, 2024, 6:32 PM EDT - 7 months ago

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

May 21, 2024, 8:39 AM EDT - 9 months ago

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB)

BAX RENB SAGE TMCI

May 20, 2024, 4:35 AM EDT - 9 months ago

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

May 9, 2024, 8:00 AM EDT - 10 months ago

RAPT Therapeutics Reports First Quarter 2024 Financial Results

Apr 9, 2024, 12:00 PM EDT - 11 months ago

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

Apr 2, 2024, 2:10 AM EDT - 11 months ago

VKTX, JANX and these biotech stocks are surging in 2024

ARQT JANX VKTX AMLX MCRB RVNC

Mar 7, 2024, 8:00 AM EST - 1 year ago

RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 5, 2024, 4:30 PM EST - 1 year ago

RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

Feb 26, 2024, 4:00 AM EST - 1 year ago

RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Feb 20, 2024, 8:36 AM EST - 1 year ago

RAPT Therapeutics' stock plunges as FDA halts two clinical trials

Feb 20, 2024, 7:41 AM EST - 1 year ago

FDA puts on hold two Rapt Therapeutics mid-stage drug trials

Feb 20, 2024, 7:30 AM EST - 1 year ago

RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

Feb 13, 2024, 8:00 AM EST - 1 year ago

RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

Jan 31, 2024, 8:00 AM EST - 1 year ago

RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 2, 2024, 8:00 AM EST - 1 year ago

RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 27, 2023, 8:00 AM EST - 1 year ago

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

Nov 13, 2023, 8:00 AM EST - 1 year ago

RAPT Therapeutics Reports Third Quarter 2023 Financial Results

Nov 3, 2023, 12:00 PM EDT - 1 year ago

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

Nov 1, 2023, 4:05 PM EDT - 1 year ago

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November

Oct 18, 2023, 9:00 AM EDT - 1 year ago

RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Aug 30, 2023, 4:05 PM EDT - 1 year ago

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

Aug 11, 2023, 8:00 AM EDT - 1 year ago

RAPT Therapeutics Reports Second Quarter 2023 Financial Results

Jun 13, 2023, 3:59 PM EDT - 1 year ago

RAPT Therapeutics: Major Catalysts Are A Long Way Off

Jun 7, 2023, 8:00 AM EDT - 1 year ago

RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference

May 25, 2023, 5:00 PM EDT - 1 year ago

RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers

May 11, 2023, 8:00 AM EDT - 1 year ago

RAPT Therapeutics Reports First Quarter 2023 Financial Results

May 3, 2023, 8:00 AM EDT - 1 year ago

RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel

Apr 26, 2023, 4:19 PM EDT - 1 year ago

RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 30, 2023, 12:12 AM EDT - 2 years ago

RAPT Therapeutics: Potential Strong Upside Ahead

Mar 29, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma

Mar 14, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results

Feb 7, 2023, 8:00 AM EST - 2 years ago

RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference

Jan 3, 2023, 8:00 AM EST - 2 years ago

RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 8, 2022, 6:30 AM EST - 2 years ago

RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer

Nov 30, 2022, 7:05 PM EST - 2 years ago

RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress

Nov 17, 2022, 9:38 PM EST - 2 years ago

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

Nov 17, 2022, 4:24 PM EST - 2 years ago

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

Nov 10, 2022, 8:00 AM EST - 2 years ago

RAPT Therapeutics Reports Third Quarter 2022 Financial Results

Nov 9, 2022, 8:00 AM EST - 2 years ago

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences

Sep 28, 2022, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires

Aug 11, 2022, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Reports Second Quarter 2022 Financial Results

May 25, 2022, 3:07 PM EDT - 2 years ago

This Mid-Cap Firm Can Potentially Offer Biggest Oral Drug In Atopic Dermatitis, Cantor Thinks So

May 25, 2022, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Announces Private Placement Financing of $50 Million

May 23, 2022, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis